Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS

cafead

Administrator
Staff member
  • cafead   Apr 05, 2024 at 11:52: AM
via Merck on Thursday launched a Phase III trial that will evaluate its oral KRAS inhibitor candidate MK-1084 in non-small cell lung cancer patients carrying the G12C mutation in the KRAS gene.

article source
 

<